Real-time · AI · Cross-signal
BetterLife Pharma just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on BetterLife Pharma, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
BetterLife Announces Closing of a Private Placement for BETR-001 and BETR-002 Compounds
Jul 02, 2024•almost 2 years ago
Contract Type
partnership
VancouverBiotechnologyDescription
BetterLife Pharma Inc. announced the closing of a non-brokered private placement, pursuant to which the Company issued 1,750,000 units at a price of $0.10 per Unit for aggregate gross proceeds of $175,000. The company primarily focuses on developing and commercializing BETR-001 and BETR-002 compounds to treat neuro-psychiatric and neurological disorders.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months